News

Dream Global Funding I S.à r.l. Announces Offers to Purchase

Dream Global Funding I S.à r.l. Announces Offers to Purchase

TORONTO, Nov. 11, 2019 (GLOBE NEWSWIRE) — THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT IS QUALIFIED OR MAY HAVE BEEN QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 Dream Global Funding I S.à r.l. (the “Offeror”) announces invitations to […]

Lassila & Tikanoja Oyj:OMIEN OSAKKEIDEN HANKINTA 11.11.2019

Lassila & Tikanoja Oyj:OMIEN OSAKKEIDEN HANKINTA 11.11.2019

Lassila & Tikanoja OyjPÖRSSI-ILMOITUS11.11.2019            Lassila & Tikanoja Oyj:OMIEN OSAKKEIDEN HANKINTA 11.11.2019      Helsingin Pörssi         Päivämäärä11.11.2019   PörssikauppaOsto   OsakelajiLAT1V   Osakemäärä5,000osaketta  Keskihinta/ osake14.8196EUR  Kokonaishinta74,098.00EUR            Yhtiön hallussa olevat omat osakkeet 11.11.2019  tehtyjen kauppojen jälkeen: 629 725 kpl.             Lassila & Tikanoja Oyj:n puolesta        Nordea Pankki Oyj              Janne SarvikiviSami Huttunen        Lisätietoja:    talousjohtaja Valtteri Palin    puh.         www.lt.fi     Liite

Lassila & Tikanoja plc :SHARE REPURCHASE 11.11.2019

Lassila & Tikanoja plc :SHARE REPURCHASE 11.11.2019

Lassila & Tikanoja plcANNOUNCEMENT11.11.2019      Lassila & Tikanoja plc :SHARE REPURCHASE 11.11.2019   In the Helsinki Stock Exchange     Trade date11.11.2019 Bourse tradeBuy ShareLAT1V Amount5,000SharesAverage price/ share14.8196EURTotal cost74,098.00EUR      Lassila & Tikanoja plc now holds a total of 629 725 sharesincluding the shares repurchased on 11.11.2019      On behalf of Lassila & Tikanoja plc    Nordea Bank Oyj     Janne SarvikiviSami Huttunen    For more information, please : Valtteri Palin, […]

Nr. 20 2019 Storaktionærmeddelelse

Nr. 20 2019 Storaktionærmeddelelse

Solar A/S skal hermed i henhold til Kapitalmarkedslovens § 30 meddele, at FIL Limited har meddelt Solar, at FIL Limited ved salg af aktier den 8. november 2019 ikke længere ejer 5% eller mere af aktiekapitalen i Solar A/S. Med venlig hilsen Solar A/S Jens Andersen Kontaktpersoner: CEO Jens Andersen […]

No. 20 2019 Major shareholder announcement

No. 20 2019 Major shareholder announcement

Pursuant to section 30 of the Danish Capital Markets Act, Solar A/S hereby announces that FIL Limited has informed Solar that following its sale of shares on 8 November 2019, FIL Limited no longer owns 5% or more of the share capital in Solar A/S. Yours faithfully, Solar A/S Jens […]

Plasma Fractionation Market to Reach USD 38.65 Bn by 2026, Kedrion Biopharma’s FDA Approval to Create Attractive Growth Opportunities: Fortune Business Insights

Plasma Fractionation Market to Reach USD 38.65 Bn by 2026, Kedrion Biopharma’s FDA Approval to Create Attractive Growth Opportunities: Fortune Business Insights

Pune, Nov. 11, 2019 (GLOBE NEWSWIRE) — The process of separating several plasma components is called plasma fractionation. These components are separated with the help of processes such as ethanol fractionation and cryoprecipitate. The rising prevalence of congenital disorders is driving the global . Unlike pharmaceutical and biopharmaceutical industry, plasma […]

Healthcare Predictive Analytics Market To Reach USD 22,390.3 Million By 2026 | Reports And Data

Healthcare Predictive Analytics Market To Reach USD 22,390.3 Million By 2026 | Reports And Data

New york, Nov. 11, 2019 (GLOBE NEWSWIRE) — Exponential increase in healthcare database volume, increasing investments on digital tech to effectively manage available information, rising adoption of electronic health records to effectively manage patients health, adoption of advanced analytics, growing need for cost curbing tools such as healthcare predictive analytics […]

Medical Imaging Systems Market To Reach USD 36.97 Billion By 2026 | Reports And Data

Medical Imaging Systems Market To Reach USD 36.97 Billion By 2026 | Reports And Data

New York, Nov. 11, 2019 (GLOBE NEWSWIRE) — Increasing demand for early disease diagnosis, adoption of analytics and artificial intelligence in diagnostic imaging, widening scope of clinical applications, rapidly growing geriatric population base, rising prevalence of associated diseases, technological advancements in the diagnostic imaging industry, and increasing investments, funds, and […]

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: First study to demonstrate a strong association between liver fat reduction by a pharmaceutical agent and improvement and resolution of NASH on liver biopsy CONSHOHOCKEN, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, […]